Al Hammadi Anwar, Pakran Jaheersha, Farghaly Mohamed, Ahmed Haytham Mohamed, Cha Amy, Balkan Dilara, Afifi Sherif, Ramachandrachar Badarinath Chickballapur, Natarajan Ashok, Linga Sreenivasulu, Al Jefri Khadija
Dermamed Clinic, Dubai, UAE.
M.D. Dermatology, Rashid Hospital, Dubai Health Authority, Dubai, UAE.
Dermatol Ther (Heidelb). 2022 Jul 19:1-25. doi: 10.1007/s13555-022-00769-z.
Atopic dermatitis (AD) data are scarce in Dubai [United Arab Emirates (UAE)]. Therefore, this study aimed at understanding real-world healthcare resource utilization (HCRU) and related costs, specialties, treatment landscape, consultation-based prevalence and incidence, and patient characteristics.
This retrospective, longitudinal, insurance e-claims (Dubai Private Insurance-insured expatriates) database studied AD in Dubai between 1 January 2014 and 31 March 2020. Two cohorts of patients based on treatment status as the eligibility criteria were selected from 442,956 patients with at least two AD diagnosis claims: treated AD [mild to moderate (10,134 patients) and moderate to severe (3515 patients)] and untreated or on drugs not included in the treated AD cohort (10,806 patients).
Across treated AD (mild to moderate and moderate to severe) and untreated AD cohorts, mean age was ~ 29 years; the majority were from dermatology (65-44%) and pediatrics (29-32%) specialty. Key HCRU cost contributors were hospitalizations and outpatient visits in both the treated AD groups. Mean annual disease-specific HCRU cost per patient was highest for the moderate-to-severe treated (531.5 USD) cohort, followed by the mild-to-moderate treated (378.4 USD) cohort, and lowest for the untreated (144.0 USD) cohort; patients with AD with any infection, asthma, or allergic rhinitis showed a similar trend. However, AD-diagnosed patients with infection had the highest mean HCRU cost among the mild-to-moderate treated AD cohort, followed by the moderate-to-severe treated AD cohort.
This study indicated AD to be a common skin disease with a prevalence rate of 4-5% in Dubai (UAE), with the majority of patients (about 90%) being treated by specialists. However, there is a significant underuse of newer innovative therapies (including biologics). Also, disease severity (moderate-to-severe AD) was associated with high direct medical cost, which could be controlled by early intervention. Furthermore, AD treatment choice could focus on major direct HCRU cost contributors such as hospitalizations, comorbid conditions, and infections.
The online version contains supplementary material available at 10.1007/s13555-022-00769-z.
在迪拜[阿拉伯联合酋长国（阿联酋）]，特应性皮炎（AD）的数据稀缺。因此，本研究旨在了解实际医疗资源利用（HCRU）及相关成本、专科、治疗格局、基于会诊的患病率和发病率，以及患者特征。
本回顾性纵向保险电子索赔（迪拜私人保险参保的外籍人士）数据库研究了2014年1月1日至2020年3月31日期间迪拜的AD。根据治疗状态作为纳入标准，从442956例至少有两项AD诊断索赔的患者中选取了两组患者：接受治疗的AD[轻度至中度（10134例患者）和中度至重度（3515例患者）]以及未接受治疗或使用的药物不在接受治疗的AD队列中的患者（10806例患者）。
在接受治疗的AD（轻度至中度和中度至重度）和未接受治疗的AD队列中，平均年龄约为29岁；大多数患者来自皮肤科（65%-44%）和儿科（29%-32%）专科。两个接受治疗的AD组中，关键的HCRU成本贡献因素都是住院和门诊就诊。每位患者每年特定疾病的HCRU成本，中度至重度治疗组最高（531.5美元），其次是轻度至中度治疗组（378.4美元），未接受治疗组最低（144.0美元）；患有任何感染、哮喘或过敏性鼻炎的AD患者也呈现类似趋势。然而，在轻度至中度治疗的AD队列中，诊断为AD且伴有感染的患者平均HCRU成本最高，其次是中度至重度治疗的AD队列。
本研究表明AD是一种常见皮肤病，在迪拜（阿联酋）的患病率为4%-5%，大多数患者（约90%）由专科医生治疗。然而，新型创新疗法（包括生物制剂）的使用明显不足。此外，疾病严重程度（中度至重度AD）与高昂的直接医疗成本相关，可通过早期干预加以控制。此外，AD治疗选择可侧重于住院、合并症和感染等主要直接HCRU成本贡献因素。
在线版本包含可在10.1007/s13555-022-00769-z获取的补充材料。
